Beneficial Effects of Korean Traditional Diets in Subjects With Hypertension and Type 2 Diabetes
Primary Purpose
Diabetes Mellitus, Type 2
Status
Completed
Phase
Not Applicable
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Korean traditional diets
Control group
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 2 focused on measuring Korean Traditional diets, hypertension, diabetes
Eligibility Criteria
Inclusion Criteria:
- Subjects who are men and women volunteers 19~80years
- Subject who have hypertension and type 2diabetes.
- Subject who have taking oral medications :
(hypoglycemic, blood pressure and lipid modifying drugs).
- Subject must provide written informed consent to participate in the study.
Exclusion Criteria:
- Subject with a history or evidence of clinically significant gastrointestinal,anorectal, hepatic, renal, neurological, pulmonary, endocrine, blood tumor,psychiatric.
- Hypertension(DBP>116mmHg or SBP>200 mmHg) having the history of cardiovascular events or taking medications known to affect lipoprotein metabolism.
- Having Type 1 diabetes mellitus or uncontrolled Type 2 diabetes mellitus (HbA1c >9.0%).
- Subjects with the history of cancer.
- Subjects who have a gastrointestinal (GI) disease (Crohn's disease, etc.) that would increase the influence with absorbance medication or a GI surgery excluding appendectomy and hernia surgery.
- Having digestive, or central nervous system disorders.
- Subject is hematologic, or neuroretinopathy.
- Subject with uterine fibroids at ultrasonography.
- Having severe or malignant retinopathy.
- Having the impairment of renal and liver function, dysproteinemia, nephritic syndrome, or other renal disease.
- Having coagulopathy
- Having human immunodeficiency virus.
- Having the history of mental instability and of drug and alcohol.
- Having the history of reactions to our experimental products.
- Participating in other clinical trials within the past 2 months.
- Having laboratory tests, medical or psychological conditions deemed by the investigators to interfere with successful participation in the study.
- Having the history of alcohol or substance abuse.
- Subject is pregnant, planning to become pregnant, or breast-feeding.
Sites / Locations
- Clinical Trial Center for Functional Foods; Chonbuk National University Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Korean traditional diets
Control group
Arm Description
Korean traditional diets (calorie 2,100kcal) for 12weeks
Control group : told to "eat as usal diet) for 12weeks
Outcomes
Primary Outcome Measures
HbA1C :Glycated Hemoglobin
Glycated Hemoglobin is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
Secondary Outcome Measures
TG :Triglycerides
Triglycerides is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
TC :Total cholesterol
Total cholesterol is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
HDL-C :High Density Lipoprotein-Cholesterol
HDL-C is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
LDL-C : Low Density Lipoprotein-Cholesterol
LDL-C is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
Breathing score
Breathing score is measured in study visits to the clinic, week 0(baseline)and week 12.
Valsalva score
Valsalva score is measured in study visits to the clinic, week 0(baseline)and week 12.
Upright score
Upright score is measured in study visits to the clinic, week 0(baseline) and week 12.
ApoA1 :Apolipoprotein A1
Apolipoprotein A1 is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
ApoB :Apolipoprotein B
Apolipoprotein B is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
Apo E :Apolipoprotein E
Apolipoprotein E is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
Free fatty acid
Free fatty acid is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
Adiponectin
Adiponectin is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
PAI-1 :Plasminogen activator inhibitor type 1
PAI-1 is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
Homocysteine
Homocysteine is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
FPG :Fasting plasma glucose
Fasting plasma glucose is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
DBP:Diastolic Blood Pressure
DBP is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
SBP:Systolic Blood Pressure
SBP is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
Heart rate
Heart rate is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
Full Information
NCT ID
NCT01724645
First Posted
October 29, 2012
Last Updated
November 9, 2012
Sponsor
Chonbuk National University Hospital
1. Study Identification
Unique Protocol Identification Number
NCT01724645
Brief Title
Beneficial Effects of Korean Traditional Diets in Subjects With Hypertension and Type 2 Diabetes
Official Title
Randomized, Open Label, Parallel Controlled, to Evaluate the Beneficial Effects of Korean Traditional Dites in Subjects With Hypertension and Type 2 Diabetes.
Study Type
Interventional
2. Study Status
Record Verification Date
November 2012
Overall Recruitment Status
Completed
Study Start Date
September 2010 (undefined)
Primary Completion Date
January 2011 (Actual)
Study Completion Date
February 2011 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Chonbuk National University Hospital
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This trial is being conducted to look for following changes when Korean traditional diets is taken in subjects with hypertension and type 2 diabetes:
To evaluate the improvement of the controlling fasting blood glucose and glycated hemoglobin.
To assess the controlling blood pressure and heart rate.
To evaluate the influence on cardiovascular risk factor, Triglyceride, cholesterol, High Density Lipoprotein-cholesterol and Low-Density Lipoprotein-cholesterol.
To evaluate the influence on Gamma-Glutamyl Transpeptidase.
To evaluate the influence on Cardiovascular risk factor.
To evaluate the influence on valsava score, breathing score and upright score.
Detailed Description
The investigators aimed to investigate the efficacy of Korean traditional diets in controlling fasting blood glucose fluctuation, blood pressure, and cardiovascular risk factors in hypertensive and type 2 diabetic patients who were taking medications prescribed for respective diseases in a 12-week.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
Keywords
Korean Traditional diets, hypertension, diabetes
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
48 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Korean traditional diets
Arm Type
Experimental
Arm Description
Korean traditional diets (calorie 2,100kcal) for 12weeks
Arm Title
Control group
Arm Type
Active Comparator
Arm Description
Control group : told to "eat as usal diet) for 12weeks
Intervention Type
Dietary Supplement
Intervention Name(s)
Korean traditional diets
Other Intervention Name(s)
The Korean Traditonal diets
Intervention Description
The consumption of Korean traditional diets reflecting the characteristics of Korean traditional diets without the limitation of calories has an effect on control of cardiovascular risk factor, so this study instructed all subjects of the intervention group to consume about 2,100kcal of served meals freely.
The Korean Traditional diets, which encourages the intake of cooked rice, vegetables,soup,Kimchi and soy fermented foods.
Intervention Type
Dietary Supplement
Intervention Name(s)
Control group
Other Intervention Name(s)
Control diets
Intervention Description
Told to " eat as usal diets".
Primary Outcome Measure Information:
Title
HbA1C :Glycated Hemoglobin
Description
Glycated Hemoglobin is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
Time Frame
84days
Secondary Outcome Measure Information:
Title
TG :Triglycerides
Description
Triglycerides is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
Time Frame
84days
Title
TC :Total cholesterol
Description
Total cholesterol is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
Time Frame
84days
Title
HDL-C :High Density Lipoprotein-Cholesterol
Description
HDL-C is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
Time Frame
84days
Title
LDL-C : Low Density Lipoprotein-Cholesterol
Description
LDL-C is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
Time Frame
84days
Title
Breathing score
Description
Breathing score is measured in study visits to the clinic, week 0(baseline)and week 12.
Time Frame
84days
Title
Valsalva score
Description
Valsalva score is measured in study visits to the clinic, week 0(baseline)and week 12.
Time Frame
84days
Title
Upright score
Description
Upright score is measured in study visits to the clinic, week 0(baseline) and week 12.
Time Frame
84days
Title
ApoA1 :Apolipoprotein A1
Description
Apolipoprotein A1 is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
Time Frame
84days
Title
ApoB :Apolipoprotein B
Description
Apolipoprotein B is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
Time Frame
84days
Title
Apo E :Apolipoprotein E
Description
Apolipoprotein E is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
Time Frame
84days
Title
Free fatty acid
Description
Free fatty acid is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
Time Frame
84days
Title
Adiponectin
Description
Adiponectin is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
Time Frame
84days
Title
PAI-1 :Plasminogen activator inhibitor type 1
Description
PAI-1 is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
Time Frame
84days
Title
Homocysteine
Description
Homocysteine is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
Time Frame
84days
Title
FPG :Fasting plasma glucose
Description
Fasting plasma glucose is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
Time Frame
84days
Title
DBP:Diastolic Blood Pressure
Description
DBP is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
Time Frame
84days
Title
SBP:Systolic Blood Pressure
Description
SBP is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
Time Frame
84days
Title
Heart rate
Description
Heart rate is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
Time Frame
84days
Other Pre-specified Outcome Measures:
Title
weight
Description
weight is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
Time Frame
84days
Title
BMI:Body Mass Index
Description
BMI is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
Time Frame
84days
Title
Body fat percent
Description
Body fat percent is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
Time Frame
84days
Title
Waist
Description
Waist is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.
Time Frame
84days
Title
Obesity associated gut microbiome(Bacteriodetes)
Description
Bacteriodetes is measured in study visits to the clinic, week 0(baseline)and week 12.
Time Frame
84days
Title
Obesity associated gut microbiome(Firmicutes)
Description
Firmicutes is measured in study visits to the clinic, week 0(baseline)and week 12.
Time Frame
84days
Title
Hypoglycemic(oral medication)
Description
Hypoglycemic oral medication is measured in study 0wk, 4wk, 8wk and 12wk.
Time Frame
84days
Title
Control blood pressure(oral medication)
Description
Control blood pressure(oral medication) is measured in study 0wk, 4wk, 8wk and 12wk.
Time Frame
84days
Title
Lipid modifying (oral medication)
Description
Lipid modifying (oral medication) is measured in study 0wk, 4wk, 8wk and 12wk.
Time Frame
84days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subjects who are men and women volunteers 19~80years
Subject who have hypertension and type 2diabetes.
Subject who have taking oral medications :
(hypoglycemic, blood pressure and lipid modifying drugs).
Subject must provide written informed consent to participate in the study.
Exclusion Criteria:
Subject with a history or evidence of clinically significant gastrointestinal,anorectal, hepatic, renal, neurological, pulmonary, endocrine, blood tumor,psychiatric.
Hypertension(DBP>116mmHg or SBP>200 mmHg) having the history of cardiovascular events or taking medications known to affect lipoprotein metabolism.
Having Type 1 diabetes mellitus or uncontrolled Type 2 diabetes mellitus (HbA1c >9.0%).
Subjects with the history of cancer.
Subjects who have a gastrointestinal (GI) disease (Crohn's disease, etc.) that would increase the influence with absorbance medication or a GI surgery excluding appendectomy and hernia surgery.
Having digestive, or central nervous system disorders.
Subject is hematologic, or neuroretinopathy.
Subject with uterine fibroids at ultrasonography.
Having severe or malignant retinopathy.
Having the impairment of renal and liver function, dysproteinemia, nephritic syndrome, or other renal disease.
Having coagulopathy
Having human immunodeficiency virus.
Having the history of mental instability and of drug and alcohol.
Having the history of reactions to our experimental products.
Participating in other clinical trials within the past 2 months.
Having laboratory tests, medical or psychological conditions deemed by the investigators to interfere with successful participation in the study.
Having the history of alcohol or substance abuse.
Subject is pregnant, planning to become pregnant, or breast-feeding.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Soo-Wan Chae, MD., PhD
Organizational Affiliation
Chonbuk National University Hospital
Official's Role
Study Director
Facility Information:
Facility Name
Clinical Trial Center for Functional Foods; Chonbuk National University Hospital
City
Jeonju
State/Province
Jeollabuk-do
ZIP/Postal Code
560-822
Country
Korea, Republic of
12. IPD Sharing Statement
Learn more about this trial
Beneficial Effects of Korean Traditional Diets in Subjects With Hypertension and Type 2 Diabetes
We'll reach out to this number within 24 hrs